Search

Displaying results 6861 - 6870 of 10000 in total
  1. Drug

    Ertumaxomab

    go.drugbank.com/drugs/DB18923
    Investigational

    Ertumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy).

  2. Drug

    Oremepermin alfa

    go.drugbank.com/drugs/DB27148
    Investigational

    Oremepermin alfa is a recombinant human hepatocyte growth factor (isoform 3) and glycoprotein composed of an α-chain and a β-chain.[L54006] It is produced in CHO cells.[L54006]

  3. Drug

    Remetinostat

    go.drugbank.com/drugs/DB14869
    Investigational

    Remetinostat is under investigation in clinical trial NCT02213861 (Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma).

  4. Drug

    Isatoribine

    go.drugbank.com/drugs/DB04860
    Experimental

    Isatoribine is a selective agonist of TLR7.

  5. Drug

    SB-743921

    go.drugbank.com/drugs/DB05546
    Investigational

  6. Drug

    Retaspimycin

    go.drugbank.com/drugs/DB05626
    Investigational

  7. Drug

    Cathine

    go.drugbank.com/drugs/DB01486
    ExperimentalIllicit

    In the United States, it is classified as a Schedule IV controlled substance. … Cathine, also known as d-norpseudoephedrine and (+)-norpseudoephedrine, is a psychoactive drug with stimulant properties. It belongs to the phenethylamine and amphetamine chemical classes.

  8. Drug

    HE-2200

    go.drugbank.com/drugs/DB06257
    Experimental

  9. Drug

    Growth hormone-releasing peptide 1

    go.drugbank.com/drugs/DB19259
    Investigational

    , and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis). … Growth hormone-releasing peptide 1 is under investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics

  10. Drug

    Elraglusib

    go.drugbank.com/drugs/DB16047
    Investigational

    Elraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).